EWM
KERX

Elite Wealth Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Elite Wealth Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-33
Closed – – 742
2013
Q4 		$0 Buy
+33
New +$394 ﹤0.01% 935

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Elite Wealth Management's KERX Position: Q1 2014 in Review

Elite Wealth Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2014, closing a stake of 33 shares.

Elite Wealth Management first reported a position in KERX in Q4 2013 and held it in 1 quarter. The position peaked at $0 in Q4 2013. 150 funds tracked by Wall St. Rank hold KERX as of Q1 2014.

  • Elite Wealth Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2014 after selling out during the quarter.
  • Elite Wealth Management sold 33 Keryx Biopharmaceuticals Inc shares in Q1 2014.
  • Elite Wealth Management first reported a position in Keryx Biopharmaceuticals Inc in Q4 2013 and held it in 1 quarter.
  • Elite Wealth Management's Keryx Biopharmaceuticals Inc position peaked at $0 in Q4 2013.
  • 150 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2014.

Based on Elite Wealth Management's 13F filing for Q1 2014, filed 23 Nov 2016.